Clinical Rheumatology

, Volume 31, Issue 9, pp 1289–1292 | Cite as

Subsequent entry biologics/biosimilars: a viewpoint from Canada

  • Anthony S. Russell
  • Vandana Ahluwalla
  • Cheryl Barnabe
  • Shahin Jamal
  • Robert C. Offer
  • Wojciech P. Olszynski
  • Kam Shojania
  • Boulos Haraoui
Review Article

Abstract

We have reviewed the issues surrounding the advent of biosimilars in the rheumatoid arthritis biologic field. Our proposals emphasize the need to focus primarily on patient safety and to assess the outcomes of therapy both in the short and longer term.

Keywords

Biosimilars Subsequent entry biologics 

References

  1. 1.
    Kanis JA, Reginster J-Y, Kaufman J-M et al (2012) A reappraisal of generic bisphonates in osteoporosis. Osteoporos Int 23:213–221PubMedCrossRefGoogle Scholar
  2. 2.
    Colbert RA, Cronstein BN (2011) Biosimilars: the debate continues. Arthritis Rheum 63:2848–2850PubMedCrossRefGoogle Scholar
  3. 3.
    Mullard A (2010) Hearing shines spotlight on biosimilar controversies. Nature Rev(Drug Discovery) 9:905–906CrossRefGoogle Scholar
  4. 4.
    Sekhon BS, Saluja V (2011) Biosimilars: an overview. Biosimilars 1:1–11Google Scholar
  5. 5.
    Kogan LA (2011) The US biologics price competition and Innovation Act of 2009 triggers public debate, regulatory/policy risks and international trade concerns. Global Trade Customs J 6:1–34Google Scholar
  6. 6.
    Joshi SR (2011) Biosimilar peptides: need for pharmacovigilance. J Assoc Physicians India 59 suppl:44–47PubMedGoogle Scholar
  7. 7.
    Rudick RA, Simonian NA, Alam JA et al (1998) Incidence and significance of neutralizing antibodies to interferon-beta1a in multiple sclerosis. Neurology 50:1266–1272PubMedCrossRefGoogle Scholar
  8. 8.
    Jelkmann W (2010) Biosimilar erythropoietins and other follow-on biologics: update on the European experience. Am J Haematol 85:771–780CrossRefGoogle Scholar
  9. 9.
    Gu N, Yi S, Kim T-E, Shin S-G, Jang I-J, Yu K-S (2011) Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence cross-over study in healthy Korean male volunteers. Clin Therapeutics 33:2029–2037CrossRefGoogle Scholar
  10. 10.

Copyright information

© Clinical Rheumatology 2012

Authors and Affiliations

  • Anthony S. Russell
    • 1
  • Vandana Ahluwalla
    • 2
  • Cheryl Barnabe
    • 3
  • Shahin Jamal
    • 4
  • Robert C. Offer
    • 5
  • Wojciech P. Olszynski
    • 6
  • Kam Shojania
    • 7
  • Boulos Haraoui
    • 8
  1. 1.562 Heritage Medical CentreUniversity of AlbertaEdmontonCanada
  2. 2.BramptonCanada
  3. 3.University of CalgaryCalgaryCanada
  4. 4.Vancouver Coastal Health Gordon and Leslie Diamond CentreVancouverCanada
  5. 5.PentictonCanada
  6. 6.Centre 103 Midtown Medical CentreSaskatoonCanada
  7. 7.Division of RheumatologyUniversity of British ColumbiaVancouverCanada
  8. 8.University of MontrealMontrealCanada

Personalised recommendations